Cargando…

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor

BACKGROUND: Bone-related extramedullary disease (EMD-B) is mass of clonal plasma cells derived from adjacent bone lesions and has obvious heterogeneities in clinical outcomes. This retrospective study aims to evaluate the treatment outcomes and long-term prognosis of newly diagnosed myeloma patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ying, Liu, Aijun, Xu, Tingting, Yin, Jiahui, Chen, Wenming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301125/ https://www.ncbi.nlm.nih.gov/pubmed/35875418 http://dx.doi.org/10.1177/11795549221109500

Ejemplares similares

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

P934: THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Tao, Yi, et al.
Publicado: (2023)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
por: Hu, Ying, et al.
Publicado: (2019)

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction
por: Cook, Joselle, et al.
Publicado: (2017)

Multiple myeloma with extramedullary plasmacytoma invading the skin and eyeballs following autologous stem cell transplantation: A case report
por: YANG, GUANGZHONG, et al.
Publicado: (2013)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
por: Engel, Nils W., et al.
Publicado: (2020)

Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients
por: Bao, Li, et al.
Publicado: (2020)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in China
por: Ge, Jingjing, et al.
Publicado: (2022)

A prognostic model for patients with primary extramedullary multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Extramedullary disease in multiple myeloma
por: Bansal, Radhika, et al.
Publicado: (2021)

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
por: Ludwig, Heinz, et al.
Publicado: (2016)

Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis
por: Tian, Chen, et al.
Publicado: (2018)

Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance
por: Chen, Hai-Fei, et al.
Publicado: (2012)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
por: Pang, Yanbin, et al.
Publicado: (2020)

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
por: Shan, Xinhe, et al.
Publicado: (2023)

Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease
por: Li, Wei, et al.
Publicado: (2022)

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023)

Multiple myeloma with huge extramedullary plasmacytomas
por: Bae, Soo-Young, et al.
Publicado: (2010)

Extramedullary Multiple Myeloma with Hepatic Involvement
por: Singh, Manpreet, et al.
Publicado: (2021)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6rjj4sh28t0pouq6nk5qqfpbsb